Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Novartis
Federal Trade Commission
Farmers Insurance
Cerilliant
Medtronic
Healthtrust
QuintilesIMS
Express Scripts
McKinsey

Generated: October 16, 2017

DrugPatentWatch Database Preview

VIVLODEX Drug Profile

« Back to Dashboard

Which patents cover Vivlodex, and what generic Vivlodex alternatives are available?

Vivlodex is a drug marketed by Iroko Pharms Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in fourteen countries.

The generic ingredient in VIVLODEX is meloxicam. There are twenty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

Summary for Tradename: VIVLODEX

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list86
Patent Applications: see list8,599
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIVLODEX at DailyMed

Pharmacology for Tradename: VIVLODEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VIVLODEX

Drugname Dosage Strength RLD Submissiondate
meloxicamCapsules5 mg and 10 mgVivlodex1/9/2017

International Patent Family for Tradename: VIVLODEX

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2015191595► Subscribe
Eurasian Patent Organization201692392► Subscribe
Australia2015274838► Subscribe
European Patent Office3151835► Subscribe
African Regional IP Organization (ARIPO)201609611► Subscribe
South Korea20170017915► Subscribe
Mexico2016016212► Subscribe
Singapore11201610179Q► Subscribe
China107073010► Subscribe
Uruguay36172► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Medtronic
Farmers Insurance
Cipla
McKesson
UBS
Merck
Mallinckrodt
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot